Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

405 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Potential of incretin-based therapies for non-alcoholic fatty liver disease.
Samson SL, Bajaj M. Samson SL, et al. Among authors: bajaj m. J Diabetes Complications. 2013 Jul-Aug;27(4):401-6. doi: 10.1016/j.jdiacomp.2012.12.005. Epub 2013 Jan 24. J Diabetes Complications. 2013. PMID: 23352496 Review.
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Sathyanarayana P, et al. Among authors: bajaj m. Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9. Obesity (Silver Spring). 2011. PMID: 21660077 Clinical Trial.
Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model.
Samson SL, Gonzalez EV, Yechoor V, Bajaj M, Oka K, Chan L. Samson SL, et al. Among authors: bajaj m. Mol Ther. 2008 Nov;16(11):1805-12. doi: 10.1038/mt.2008.198. Epub 2008 Sep 9. Mol Ther. 2008. PMID: 18781141 Free PMC article.
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA. Bajaj M, et al. Diabetes. 2003 Jun;52(6):1364-70. doi: 10.2337/diabetes.52.6.1364. Diabetes. 2003. PMID: 12765945
The effect of pioglitazone on splanchnic glucose uptake (SGU), endogenous glucose production (EGP), and hepatic fat content was studied in 14 type 2 diabetic patients (age 50 +/- 2 years, BMI 29.4 +/- 1.1 kg/m(2), HbA(1c) 7.8 +/- 0.4%). ...Subjects received a 7-h euglycemi …
The effect of pioglitazone on splanchnic glucose uptake (SGU), endogenous glucose production (EGP), and hepatic fat content was studied in 1 …
Nicotine and insulin resistance: when the smoke clears.
Bajaj M. Bajaj M. Diabetes. 2012 Dec;61(12):3078-80. doi: 10.2337/db12-1100. Diabetes. 2012. PMID: 23172960 Free PMC article. No abstract available.
The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes.
Gutierrez AD, Sathyanarayana P, Konduru S, Ye Y, Birnbaum Y, Bajaj M. Gutierrez AD, et al. Among authors: bajaj m. Atherosclerosis. 2012 Jul;223(1):204-8. doi: 10.1016/j.atherosclerosis.2012.04.016. Epub 2012 May 7. Atherosclerosis. 2012. PMID: 22687642 Clinical Trial.
miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity.
Koh EH, Chernis N, Saha PK, Xiao L, Bader DA, Zhu B, Rajapakshe K, Hamilton MP, Liu X, Perera D, Chen X, York B, Trauner M, Coarfa C, Bajaj M, Moore DD, Deng T, McGuire SE, Hartig SM. Koh EH, et al. Among authors: bajaj m. Diabetes. 2018 Dec;67(12):2541-2553. doi: 10.2337/db17-1378. Epub 2018 Jul 12. Diabetes. 2018. PMID: 30002134 Free PMC article.
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y, Bajaj M, Yang HC, Ye Y. Birnbaum Y, et al. Among authors: bajaj m. Cardiovasc Drugs Ther. 2018 Apr;32(2):135-145. doi: 10.1007/s10557-018-6778-x. Cardiovasc Drugs Ther. 2018. PMID: 29508169
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials.
Jia X, Alam M, Ye Y, Bajaj M, Birnbaum Y. Jia X, et al. Among authors: bajaj m. Cardiovasc Drugs Ther. 2018 Feb;32(1):65-72. doi: 10.1007/s10557-018-6773-2. Cardiovasc Drugs Ther. 2018. PMID: 29445896
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. Ye Y, et al. Among authors: bajaj m. Cardiovasc Drugs Ther. 2017 Apr;31(2):119-132. doi: 10.1007/s10557-017-6725-2. Cardiovasc Drugs Ther. 2017. PMID: 28447181
405 results
Jump to page
Feedback